{"id":119564,"date":"2026-05-01T11:32:20","date_gmt":"2026-05-01T15:32:20","guid":{"rendered":"https:\/\/www.businessupturn.com\/usa\/?p=119564"},"modified":"2026-05-01T11:32:20","modified_gmt":"2026-05-01T15:32:20","slug":"rhythm-pharmaceuticals-stock-rises-after-europe-approves-imcivree-for-rare-obesity-disorder","status":"publish","type":"post","link":"https:\/\/www.businessupturn.com\/usa\/rhythm-pharmaceuticals-stock-rises-after-europe-approves-imcivree-for-rare-obesity-disorder\/119564\/","title":{"rendered":"Rhythm Pharmaceuticals stock rises after Europe approves Imcivree for rare obesity disorder"},"content":{"rendered":"
\n
\n
\n
\n

Shares of Rhythm Pharmaceuticals<\/span><\/span> moved up by 2.6% on Friday. The stock reached $83.45 after fresh news from Europe. The company confirmed that the European Commission<\/span><\/span> has approved its obesity drug.<\/p>\n

This approval is important. It opens access to a new market. It also validates the company\u2019s research work. Investors reacted positively, even though the rise was modest.<\/p>\n

The stock has still struggled this year. It is down 22.3% so far. This shows that one approval is helpful, but not enough to fully change market sentiment yet.<\/p>\n

Imcivree approval for hypothalamic obesity treatment<\/h2>\n

The drug, called Imcivree<\/span><\/span>, is now approved in Europe. It will be used for people with hypothalamic obesity. This is a rare condition. It happens when the hypothalamus gets damaged.<\/p>\n

The hypothalamus controls hunger. When it is injured, people feel constant hunger. This leads to rapid weight gain. The condition is very hard to manage with normal diets or exercise.<\/p>\n

Imcivree works by targeting the hunger pathway. It helps control appetite. It can be used in adults and children aged 4 and above.<\/p>\n

This is a major step. It becomes the first approved treatment in Europe for this condition. That gives it a strong position in the market.<\/p>\n

Europe launch plans and future outlook<\/h2>\n

Rhythm Pharmaceuticals<\/span><\/span> is not launching the drug immediately. The company plans to roll it out in 2027. It will first apply for access in each country. This is a standard process in Europe.<\/p>\n

The drug already received approval in the United States in March. That gives the company experience in commercialization. Europe is the next big step.<\/p>\n

The long timeline may test investor patience. But the opportunity is clear. Rare disease treatments often have strong pricing power. They also face limited competition.<\/p>\n

For now, the stock reaction is cautious. The approval is a win. But the market wants to see real revenue growth in the coming years.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Shares of Rhythm Pharmaceuticals moved up by 2.6% on Friday. The stock reached $83.45 after fresh news from Europe. The\u2026<\/p>\n","protected":false},"author":294,"featured_media":119565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73],"tags":[36257],"class_list":["post-119564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-us-markets","tag-rhythm-pharmaceuticals"],"reading_time":"2 min read","_links":{"self":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/119564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/users\/294"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/comments?post=119564"}],"version-history":[{"count":1,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/119564\/revisions"}],"predecessor-version":[{"id":119566,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/posts\/119564\/revisions\/119566"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media\/119565"}],"wp:attachment":[{"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/media?parent=119564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/categories?post=119564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessupturn.com\/usa\/wp-json\/wp\/v2\/tags?post=119564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}